Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003050908 | SCV003445425 | uncertain significance | Multiple endocrine neoplasia, type 2 | 2023-01-07 | criteria provided, single submitter | clinical testing | Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. This variant has not been reported in the literature in individuals affected with RET-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.006%). This sequence change falls in intron 18 of the RET gene. It does not directly change the encoded amino acid sequence of the RET protein. It affects a nucleotide within the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
All of Us Research Program, |
RCV003050908 | SCV004826606 | likely benign | Multiple endocrine neoplasia, type 2 | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004948946 | SCV005490970 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-18 | criteria provided, single submitter | clinical testing | The c.3040-3C>T intronic variant results from a C to T substitution 3 nucleotides upstream from coding exon 19 in the RET gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on the available evidence, the clinical significance of this variant remains unclear. |